Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22200697 | 0.84 | BRAF (0.40) | BRAFEGFRFGFR1SRCFGFR2 | |
| SCHEMBL25034179 | 0.84 | BRAF (0.46) | BRAF | |
| SCHEMBL22200682 | 0.74 | FGFR1 (0.44) | BRAFEGFRFGFR1SRCFGFR2 | |
| SCHEMBL22200721 | 0.73 | RORC (0.35) | BRAF | |
| SCHEMBL22200335 | 0.73 | WEE1 (0.34) | BRAFFGFR1ABL1 | |
| SCHEMBL25035525 | 0.73 | BRAF (0.51) | BRAF | |
| SCHEMBL25035620 | 0.72 | BRAF (0.49) | BRAF | |
| SCHEMBL22200701 | 0.72 | ERN1 (0.42) | BRAFPIK3CAEGFRFGFR1SRC | |
| SCHEMBL25035437 | 0.71 | BRAF (0.45) | BRAFPAK1 | |
| SCHEMBL25035672 | 0.70 | BRAF (0.56) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |